Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand

References

• Bouxsein ML, Karasik D. Bone geometry and skeletal fragility. Curr Osteoporos Rep. 2006;4(2):49–56.
   PubMedGoogle Scholar
• Recker R, Lappe J, Davies KM, et al. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19(10):1628–1633.
   PubMed Web of Science ®Google Scholar
• Limpaphayom KK, Taechakraichana N, Jaisamrarn U, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause. 2001;8(1):65–69.
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. Thailand: Regional Asia Audit. 2019 [cited 2019 Feb 4]; Available from: https://www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/Asian_regional_audit_Thailand.pdf.
   Google Scholar
• Lau EMC, Lee JK, Suriwongpaisal P, et al. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int. 2001;12(3):239–243.
   PubMed Web of Science ®Google Scholar
• Pongchaiyakul C, Songpattanasilp T, Taechakraichana N. Burden of osteoporosis in Thailand. J Med Assoc Thai. 2008;91(2):261–267.
   PubMedGoogle Scholar
• Jitapunkul S, Thamarpirat J, Chaiwanichsiri D, et al. Incidence of vertebral fractures in Thai women and men: a prospective population-based study. Geriatr Gerontol Int. 2008;8(4):251–258.
   PubMed Web of Science ®Google Scholar
• Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–1630.
   PubMed Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622.
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness. Denosumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture. 2017 [cited 2019 March 28]. Available from: http://www.ace-hta.gov.sg/our-guidance/denosumab-for-the-treatment-of-postmenopausal-women-with-osteoporosis-at-high-risk-of-fracture.html.
   Google Scholar
• Chau D, Becker DL, Coombes ME, et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15(sup1):3–14.
   PubMedGoogle Scholar
• Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29(10):895–911.
   PubMed Web of Science ®Google Scholar
• Jonsson B, et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22(3):967–982.
   PubMed Web of Science ®Google Scholar
• Karnon J, Shafie AS, Orji N, et al. What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc. 2016;14(1):11.
   PubMedGoogle Scholar
• Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int. 2017;28(5):1733–1744.
   PubMed Web of Science ®Google Scholar
• Parthan A, Kruse M, Yurgin N, et al. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11(5):485–497.
   PubMedGoogle Scholar
• Strom O, Jonsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int. 2013;24(4):1491–1502.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Prolia (denosumab). 2020 [cited 2020 Jan 07]. Available from: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/prolia/prolia_pi.pdf.
   Google Scholar
• Teerawattananon Y, Tritasavit N, Suchonwanich N, et al. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397–404.
   PubMedGoogle Scholar
• [cited 2019 Aug 29]. Available from: https://www.exchange-rates.org/Rate/THB/USD/12-31-2018.
   Google Scholar
• Vaseenon T, Luevitoonvechkij S, Wongtriratanachai P, et al. Long-term mortality after osteoporotic hip fracture in Chiang Mai, Thailand. J Clin Densitom. 2010;13(1):63–67.
   PubMed Web of Science ®Google Scholar
• Ministry of Commerce. Report for Consumer Price Index. 2018 [cited 2018 Aug 31]. Available from: http://www.indexpr.moc.go.th/price_present/cpi/stat/others/indexg_report2.asp?table_name.
   Google Scholar
• Werayingyong P. Health resource utilization of osteoporosis patients at phramongkutklao hospital, in pharmacy administration. 2006. Thailand: Mahidol University.
   Google Scholar
• Khongboon P, Pongpanich S. Estimating long-term care costs among thai elderly: a phichit province case study. J Aging Res. 2018;2018:1–11.
   Google Scholar
• Kingkaew P, Maleewong U, Ngarmukos C, et al. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. Value Health. 2012;15(1):S20–S8.
   PubMed Web of Science ®Google Scholar
• Health MoP. Median Unit Pricing List. 2017.
   Google Scholar
• Hiligsmann M, Ethgen O, Richy F, et al. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82(4):288–292.
   PubMed Web of Science ®Google Scholar
• Tosteson ANA, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001;12(12):1042–1049.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int. 2013;24(1):209–217.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 2007;100(12):1214–1218.
   PubMed Web of Science ®Google Scholar
• Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19(10):1421–1429.
   PubMed Web of Science ®Google Scholar
• Songpatanasilp T, Sritara C, Kittisomprayoonkul W, et al. Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. Osteoporos Sarcopenia. 2016;2(4):191–207.
   PubMedGoogle Scholar
• Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943–1951.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Actonel (risedronate sodium) tablets. [cited 2019 Aug 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf.
   Google Scholar
• Highlights of prescribing information: Fosamax (alendronate sodium). [cited 2019 Aug 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf.
   Google Scholar
• Highlights of prescribing information: Zometa (zoledronic acid). [cited 2019 Aug 15]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021223s034lbl.pdf.
   Google Scholar
• Miller PD, Jamal SA, Evenepoel P, et al. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013;28(10):2049–2059.
   PubMed Web of Science ®Google Scholar
• Suzuki HKM, Mano S, Kobayashi T, et al. Efficacy and safety of denosumab for the treatment of osteoporosis in patients with chronic kidney disease. J Clin Exp Nephrol. 2017;02(01):30.
   Google Scholar
• Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res. 2006;22(2):203–210.
   Web of Science ®Google Scholar
• Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74(6):721–731.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385–1393.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol . 2009; 4(1):221–233.
   PubMed Web of Science ®Google Scholar
• Wongtriratanachai P, Luevitoonvechkij S, Songpatanasilp T, et al. Increasing incidence of hip fracture in Chiang Mai, Thailand. J Clin Densitom. 2013;16(3):347–352.
   PubMed Web of Science ®Google Scholar
• Chaysri R, Leerapun T, Klunklin K, et al. Factors related to mortality after osteoporotic hip fracture treatment at Chiang Mai University Hospital, Thailand, during 2006 and 2007. J Med Assoc Thai. 2015;98(1):59–64.
   PubMedGoogle Scholar
• (HITAP). H.I.a.T.A. Economic evaluation of screening and treatment options for postmenopausal osteoporosis: Ministry of Public Health. 2013 [cited 2020 Feb 17]. Available from: http://hitap.net/costingmenu/.
   Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension. J Bone Miner Res. 2018;33(2):190–198.
   PubMed Web of Science ®Google Scholar
• Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–752.
   PubMed Web of Science ®Google Scholar
• Tripto-Shkolnik L, Fund N, Rouach V, et al. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. Bone. 2020;130:115150.
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, et al. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int. 2019;30(1):45–57.
   PubMed Web of Science ®Google Scholar
• Woratanarat P, Wajanavisit W, Lertbusayanukul C, et al. Cost analysis of osteoporotic hip fractures. J Med Assoc Thai. 2005;88(Suppl 5):S96–S104.
   PubMedGoogle Scholar
• IQVIA. Data from expert opinion for economic evaluation of denosumab for postmenopausal osteoporosis in Thailand. Durham: IQVIA; 2018.
   Google Scholar
• HITAP. H.I.a.T.A. Standard Cost List for Health Technology Assessment: Ministry of Public Health. 2009 [cited 2020 Feb 17]. Available from: http://hitap.net/costingmenu/.
   Google Scholar
• Ministry of Public Health. Median Unit Pricing List. Geneva: Ministry of Public Health; 2017.
   Google Scholar
• Jonsson E, et al. Systematic review and meta-analysis of persistence with denosumab in patients with osteoporosis. In ISPOR 17th Annual European Meeting. 2014. Amsterdam, The Netherlands.
   Google Scholar